DNA aptamers against the MUC1 tumour marker: design of aptamer–antibody sandwich ELISA for the early diagnosis of epithelial tumours
- 2.5k Downloads
Aptamers are functional molecules able to bind tightly and selectively to disease markers, offering great potential for applications in disease diagnosis and therapy. MUC1 is a well-known tumour marker present in epithelial malignancies and is used in immunotherapeutic and diagnostic approaches. We report the selection of DNA aptamers that bind with high affinity and selectivity an MUC1 recombinant protein containing five repeats of the variable tandem repeat region. Aptamers were selected using the SELEX methodology from an initial library containing a 25-base-long variable region for their ability to bind to the unglycosylated form of the MUC1 protein. After ten rounds of in vitro selection and amplification, more than 90% of the pool of sequences consisted of target-binding molecules, which were cloned, sequenced and found to share no sequence consensus. The binding properties of these aptamers were quantified using ELISA and surface plasmon resonance. The lead aptamer sequence was subsequently used in the design of an aptamer–antibody hybrid sandwich ELISA for the identification and quantification of MUC1 in buffered solutions. Following optimisation of the operating conditions, the resulting enzyme immunoassay displayed an EC50 value of 25 μg/ml, a detection limit of 1 μg/ml and a linear range between 8 and 100 μg/ml for the MUC1 five tandem repeat analyte. In addition, recovery studies performed in buffer conditions resulted in averaged recoveries between 98.2 and 101.7% for all spiked samples, demonstrating the usability of the aptamer as a receptor in microtitre-based assays. Our results aim towards the formation of new diagnostic assays against this tumour marker for the early diagnosis of primary or metastatic disease in breast, bladder and other epithelial tumours.
KeywordsMUC1 Aptamers ELISA Diagnostic assay Immunoassay
The authors would like to acknowledge Alan Perkins, University of Nottingham, for kindly donating the C595 anti-MUC1 control. Mark Kreuzer is acknowledged for his advice on the immunoassay development. C.S.M.F. acknowledges The Open University for financial support during her PhD. S.M. acknowledges the support of The Open University and the Breast Cancer Campaign for the further development of this project.
- 1.Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) Biochim Biophys Acta 1455:301–303Google Scholar
- 2.Jarrard JA, Linnoila RI, Lee HR, Steinberg SM, Witschi H, Szabo E (1998) Cancer Res 58:5582–5589Google Scholar
- 6.McGuckin MA, Devine PL (1995) Tumour Diagn Ther 16:1–16Google Scholar
- 12.Hicke BJ, Watson SR, Koenig A, Lynott CK, Bargatze RF, Chang YF, Ringquist S, MoonMcDermot L, Jennings S, Fitzwater T, Han HL, Varki N, Albinana I, Willis MC, Varki A, Parma D (1996) J Clin Invest 98:2688–2692Google Scholar
- 14.Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, Winnacker EL (1997) J Virol 71:8790–8797Google Scholar
- 15.Lauhon CT, Szostak JW (1994) J Am Chem Soc 14:5798–5811Google Scholar
- 20.Brody EN, Gold L (2000) J Biotechnol 74:5–13Google Scholar
- 24.Gewirtz AM (1999) Curr Opin Mol Ther 1:297–306Google Scholar
- 28.Lupold SE, Hicke J, Lin Yun C, Donald S (2002) Cancer Res 62:4029–4033Google Scholar
- 34.Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J (1999) J Clin Invest 104:913–923Google Scholar
- 42.Fujino T, Sato Y, Une M, Kanayasu-Toyoda T, Yamaguchi T, Shudo K, Inoue K, Nishimaki-Mogamiet T (2003) J Steroid Biochem 97:247–252Google Scholar